» Articles » PMID: 14673054

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Abstract

An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials. Since the original publication, there have been major advances in our understanding of the biology and molecular genetics of acute leukemia that are clinically relevant and warrant incorporation into response definitions. Differences from the 1990 recommendations included a category of leukemia-free state, new criteria for complete remission, including cytogenetic and molecular remissions and remission duration. Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders.

Citing Articles

Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.

Liu Q, Yang J, Lv L, Zhang X, Li M, Xu L Front Immunol. 2025; 16:1525110.

PMID: 40079007 PMC: 11897025. DOI: 10.3389/fimmu.2025.1525110.


Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

DiNardo C, Jen W, Takahashi K, Kadia T, Loghavi S, Daver N Leukemia. 2025; .

PMID: 40000842 DOI: 10.1038/s41375-025-02531-8.


Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

Abedin S, Guru Murthy G, Hamadani M, Michaelis L, Carlson K, Runaas L Leukemia. 2025; .

PMID: 39955432 DOI: 10.1038/s41375-025-02528-3.


Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study.

Gyan E, Minden M, Kubo K, Rambaldi A, Juliusson G, Jadersten M Cancer. 2025; 131(4):e35746.

PMID: 39945223 PMC: 11822735. DOI: 10.1002/cncr.35746.


Breakthrough Invasive Mold Infections in Hematologic Cases: Relevance of the Host's Factors.

Rodriguez-Goncer I, Boan J, Carrero-Arribas R, Sanchez-Pina J, Lizasoain M, Fernandez-Ruiz M Open Forum Infect Dis. 2025; 12(2):ofaf025.

PMID: 39917333 PMC: 11800478. DOI: 10.1093/ofid/ofaf025.